Publications - Harry J. Long III, M.D.

Back to research profile

  1. Ayeni TA, Bakkum-Gamez JN, Mariani A, McGree ME, Weaver AL, Haddock MG, Keeney GL, Long HJ 3rd, Dowdy SC, Podratz KC. Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas. Gynecol Oncol. 2013 Jun; 129(3):478-85. Epub 2013 Mar 25.
    View PubMed
  2. Chase DM, Huang HQ, Wenzel L, Cella D, McQuellon R, Long HJ, Moore DH, Monk BJ. Quality of life and survival in advanced cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 May; 125(2):315-9. Epub 2012 Feb 01.
    View PubMed
  3. Viswanathan AN, Creutzberg CL, Craighead P, McCormack M, Toita T, Narayan K, Reed N, Long H, Kim HJ, Marth C, Lindegaard JC, Cerrotta A, Small W Jr, Trimble E. International brachytherapy practice patterns: a survey of the Gynecologic Cancer Intergroup (GCIG). Int J Radiat Oncol Biol Phys. 2012 Jan 1; 82(1):250-5. Epub 2010 Dec 22.
    View PubMed
  4. Alhilli MM, Long HJ, Podratz KC, Bakkum-Gamez JN. Aromatase inhibitors in the treatment of recurrent ovarian granulosa cell tumors: brief report and review of the literature. J Obstet Gynaecol Res. 2012 Jan; 38(1):340-4. Epub 2011 Dec 05.
    View PubMed
  5. Sandhu NP, Long HJ, Johnson KJ, Degnim AC. An unusual presentation of breast cancer in a very young woman. BMJ Case Rep. 2011; 2011. Epub 2011 Mar 15.
    View PubMed
  6. Aletti GD, Nordquist D, Hartmann L, Gallenberg M, Long HJ, Cliby WA. From randomized trial to practice: single institution experience using the GOG 172 i.p. chemotherapy regimen for ovarian cancer. Ann Oncol. 2010 Sep; 21(9):1772-8. Epub 2010 Feb 05.
    View PubMed
  7. Huh WK, Sill MW, Darcy KM, Elias KM, Hoffman JS, Boggess JF, Alvarez RD, Long HJ, O'Malley DM, Birrer MJ. Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus. Gynecol Oncol. 2010 May; 117(2):248-54. Epub 2010 Feb 26.
    View PubMed
  8. Litzow MR, Peethambaram PP, Safgren SL, Keeney GL, Ansell SM, Dispenzieri A, Elliott MA, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Micallef IN, Porrata LF, Lingle WL, Hartmann LC, Frost MH, Barrette BA, Long HJ, Suman VJ, Reid JM, Ames MM, Kaufmann Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma. Bone Marrow Transplant. 2010 Mar; 45(3):490-7. Epub 2009 Aug 03.
    View PubMed
  9. Galanis E, Hartmann LC, Cliby WA, Long HJ, Peethambaram PP, Barrette BA, Kaur JS, Haluska PJ Jr, Aderca I, Zollman PJ, Sloan JA, Keeney G, Atherton PJ, Podratz KC, Dowdy SC, Stanhope CR, Wilson TO, Federspiel MJ, Peng KW, Russell SJ. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res. 2010 Feb 1; 70(3):875-82. Epub 2010 Jan 26.
    View PubMed
  10. Moore DH, Tian C, Monk BJ, Long HJ, Omura GA, Bloss JD. Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2010 Jan; 116(1):44-9. Epub 2009 Oct 22.
    View PubMed
  11. Homesley HD, Filiaci V, Gibbons SK, Long HJ, Cella D, Spirtos NM, Morris RT, DeGeest K, Lee R, Montag A. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study. Gynecol Oncol. 2009 Mar; 112(3):543-52. Epub 2008 Dec 23.
    View PubMed
  12. Hartmann L, Cliby W, Long H, Peethambaram P, Barrette B. Phase I trial of intraperitoneal administration of an engineered attenuated strain of measles virus, genetically modified to express carcinoembryonic antigen (CEA) in patients with recurrent ovarian cancer. [forthcoming] J Clin Oncol. 2009; JCO/2407.
  13. Plaxe SC, Brooks SE, Tian C, Bloss JD, Moore DH, Long HJ. Influence of race on tolerance of platinum-based chemotherapy and clinical outcomes in women with advanced and recurrent cervical cancer: a pooled analysis of 3 Gynecologic Oncology Group studies. Am J Obstet Gynecol. 2008 Nov; 199(5):539.e1-6. Epub 2008 Jun 20.
    View PubMed
  14. Long HJ 3rd, Laack NN, Gostout BS. Prevention, diagnosis, and treatment of cervical cancer. Mayo Clin Proc. 2007 Dec; 82(12):1566-74.
    View PubMed
  15. Long HJ 3rd. Management of metastatic cervical cancer: review of the literature. J Clin Oncol. 2007 Jul 10; 25(20):2966-74.
    View PubMed
  16. Aletti GD, Long HJ, Podratz KC, Cliby WA. Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer? Gynecol Oncol. 2007 Jan; 104(1):212-6. Epub 2006 Oct 04.
    View PubMed
  17. Long HJ 3rd, Nelimark RA, Podratz KC, Suman V, Keeney GL, Nikcevich DA, Kugler JW, Rowland KM Jr, Kardinal CG, Wos EJ. Phase III comparison of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) vs. doxorubicin and cisplatin (AC) in women with advanced primary or recurrent metastatic carcinoma of the uterine endometrium. Gynecol Oncol. 2006 Mar; 100(3):501-5. Epub 2005 Sep 26.
    View PubMed
  18. Long HJ 3rd, Monk BJ, Huang HQ, Grendys EC Jr, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV, Gynecologic Oncology Group. Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study. Gynecol Oncol. 2006 Mar; 100(3):537-43. Epub 2005 Oct 10.
    View PubMed
  19. Hricak H, Gatsonis C, Chi DS, Amendola MA, Brandt K, Schwartz LH, Koelliker S, Siegelman ES, Brown JJ, McGhee RB, Iyer R, Vitellas KM, Snyder B, Long HJ, Fiorica JV, Mitchell DG. Role of imaging in pretreatment evaluation of early invasive cervical cancer: Results of the Intergroup Study American College of Radiology Imaging Network 6651-Gynecologic Oncology Group 183. J Clin Oncol. 2005 Dec 20; 23(36):9329-37.
  20. Long HJ 3rd, Blessing JA, Sorosky J. Phase II trial of dacarbazine, mitomycin, doxorubicin, and cisplatin with sargramostim in uterine leiomyosarcoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2005 Nov; 99(2):339-42. Epub 2005 Jul 26.
    View PubMed
  21. Amendola MA, Hricak H, Mitchell DG, Snyder B, Chi DS, Long HJ, Fiorica JV, Gatsonis C. Utilization of diagnostic studies in the pretreatment evaluation of invasive cervical cancer in the united states: Results of intergroup protocol ACRIN 6651/GOG 183. J Clin Oncol. 2005 Oct 20; 23(30):7454-9.
    View PubMed
  22. Monk BJ, Huang HQ, Cella D, Long HJ. Quality of life outcomes from a Randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: A gynecologic oncology group study. J Clin Oncol. 2005 Jul 20; 23(21):4617-25.
    View PubMed
  23. Long HJ 3rd, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV, Gynecologic Oncology Group Study. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005 Jul 20; 23(21):4626-33. Epub 2005 May 23.
    View PubMed
  24. Mariani A, Dowdy SC, Keeney GL, Long HJ, Lesnick TG, Podratz KC. High-risk endometrial cancer subgroups: candidates for target-based adjuvant therapy. Gynecol Oncol. 2004 Oct; 95(1):120-6.
    View PubMed
  25. Advani R, Peethambaram P, Lum BL, Fisher GA, Hartmann L, Long HJ, Halsey J, Holmlund JT, Dorr A, Sikic BI. A phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma. Cancer. 2004 Jan 15; 100(2):321-6.
    View PubMed
  26. Young RC, Brady MF, Nieberg RK, Long HJ, Mayer AR, Lentz SS, Hurteau J, Alberts DS. Adjuvant treatment for early ovarian cancer: A randomized phase III trial of intraperitoneal P-32 or intravenous cyclophosphamide and cisplatin - A gynecologic oncology group study. J Clin Oncol. 2003 Dec 1; 21(23):4350-5.
    View PubMed
  27. Long HJ 3rd. Current research directions for locally advanced cervix cancer. Curr Oncol Rep. 2003 Nov; 5(6):468-72.
    View PubMed
  28. Omura GA, Brady MF, Look KY, Averette HE, Delmore JE, Long HJ, Wadler S, Spiegel G, Arbuck SG. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. J Clin Oncol. 2003 Aug 1; 21(15):2843-8. Epub 2003 Jun 13.
    View PubMed
  29. Varia MA, Stehman FB, Bundy BN, Benda JA, Clarke-Pearson DL, Alvarez RD, Long HJ. Intraperitoneal radioactive phosphorus (P-32) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: A randomized trial of the Gynecologic Oncology Group. J Clin Oncol. 2003 Aug 1; 21(15):2849-55.
    View PubMed
  30. Long HJ 3rd, Rayson S, Podratz KC, Abu-Ghazaleh S, Suman V, Hartmann LC, Levitt R, Nair S, Hatfield AK, Knost JA. Long-term survival of patients with advanced/recurrent carcinoma of cervix and vagina after neoadjuvant treatment with methotrexate, vinblastine, doxorubicin, and cisplatin with or without the addition of molgramostim, and review of the literature. Am J Clin Oncol. 2002 Dec; 25(6):547-51.
    View PubMed
  31. Dowdy SC, Boardman CH, Wilson TO, Podratz KC, Hartmann LC, Long HJ. Multimodal therapy including neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) for stage IIB to IV cervical cancer. Am J Obstet Gynecol. 2002 Jun; 186(6):1167-73.
    View PubMed
  32. Peethambaram PP, Long HJ. Second-line and subsequent therapy for ovarian carcinoma. Curr Oncol Rep. 2002 Mar; 4(2):159-64.
    View PubMed
  33. Edmonson JH, Suman VJ, Dalton RJ, Bro WC, Gallenberg MM, Long HJ, Levitt R, Hatfield AK, Krook JE, Mailliard JA, Gerstner JB, North Central Cancer Treatment Group. Comparison of conventional dose and double dose carboplatin in patients receiving cyclophosphamide plus carboplatin for advanced ovarian carcinoma: a North Central Cancer Treatment Group Study. Cancer Invest. 2001; 19(6):597-602.
    View PubMed
  34. Creagan ET, Suman VJ, Dalton RJ, Pitot HC, Long HJ, Veeder MH, Vukov AM, Rowland KM, Krook JE, Michalak JC. Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. J Clin Oncol. 1999 Jun; 17(6):1884-90.
    View PubMed
  35. Edmonson JH, Long HJ, Kvols LK, Mann BS, Grill JP. Can molgramostim enhance the antitumor effects of cytotoxic drugs in patients with advanced sarcomas? Ann Oncol. 1997 Jul; 8(7):637-41.
    View PubMed
  36. Curtin JP, Hoskins WJ, Venkatraman ES, Almadrones L, Podratz KC, Long H, Teneriello M, Averette HA, Sevin BU. Adjuvant chemotherapy versus chemotherapy plus pelvic irradiation for high-risk cervical cancer patients after radical hysterectomy and pelvic lymphadenectomy (RH-PLND): a randomized phase III trial. Gynecol Oncol. 1996 Apr; 61(1):3-10.
    View PubMed
  37. Long HJ 3rd, Langdon RM Jr, Cha SS, Veeder MH, Pfeifle DM, Krook JE, Ebbert LP, Tschetter LK, Roshon SG. Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent endometrial carcinoma. Gynecol Oncol. 1995 Aug; 58(2):240-3.
    View PubMed
  38. Long HJ 3rd, Cross WG, Wieand HS, Webb MJ, Mailliard JA, Kugler JW, Tschetter LK, Kardinal CG, Ebbert LP, Rayson S. Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent carcinoma of the uterine cervix and vagina. Gynecol Oncol. 1995 May; 57(2):235-9.
    View PubMed
  39. Ingle JN, Kuross SA, Mailliard JA, Loprinzi CL, Jung SH, Nelimark RA, Krook JE, Long HJ. Evaluation of piroxantrone in women with metastatic breast cancer and failure on nonanthracycline chemotherapy. Cancer. 1994 Sep 15; 74(6):1733-8.
    View PubMed
  40. Long HJ 3rd, Nelimark RA, Su JQ, Garneau SC, Levitt R, Goldberg RM, Poon MA, Kugler JW. Phase II evaluation of 5-fluorouracil and low-dose leucovorin in cisplatin-refractory advanced ovarian carcinoma. Gynecol Oncol. 1994 Aug; 54(2):180-3.
    View PubMed
  41. Long HJ. Paclitaxel (Taxol): a novel anticancer chemotherapeutic drug. Mayo Clin Proc. 1994 Apr; 69(4):341-5.
    View PubMed
  42. Lee TC, Hook CC, Long HJ. Severe exfoliative dermatitis associated with hand ischemia during cisplatin therapy. Mayo Clin Proc. 1994 Jan; 69(1):80-2.
    View PubMed
  43. Young RC, Brady MF, Walton LA, Homesley HD, Averette HE, Long HJ. Localized ovarian cancer in the elderly. Cancer. 1993 Jan 15; 71:601-605.
    View PubMed
  44. Edmonson JH, Hartmann LC, Long HJ, Colon-Otero G, Fitch TR, Jefferies JA, Braich TA, Maples WJ. Granulocyte-macrophage colony-stimulating factor. Preliminary observations on the influences of dose, schedule, and route of administration in patients receiving cyclophosphamide and carboplatin. Cancer. 1992 Nov 15; 70(10):2529-39.
    View PubMed
  45. Cornelissen G, Halberg F, Halberg E, Bingham C, Haus E, Bast RC Jr, Fujii S, Long HJ III, Halberg F, Tamura K. Toward a chronotherapy of ovarian cancer. Part III: Salivary CA125 for chronochemotherapy by efficacy. Chronobiologia. 1992 Jul-Dec; 19(3-4):131-49.
    View PubMed
  46. Halberg E, Long HJ III, Cornelissen G, Blank MA, Elg S, Touitou Y, Bakken E, Delmore P, Haus E, Sackett-Lundeen L, Prem K, Halberg F. Toward a chronotherapy of ovarian cancer with taxol. Part II: Test pilot study on circulating CA125. Chronobiologia. 1992 Jan-Mar; 19(1-2):17-42.
    View PubMed
  47. Hauge MD, Long HJ, Hartmann LC, Edmonson JH, Webb MJ, Su J. Phase II trial intravenous hexamethylmelamine in patients with advanced ovarian cancer. Invest New Drugs. 1992; 10:299-301.
    View PubMed
  48. Long HJ. Medicine's battle with cancer: screening still key element of armamentarium. Minn Med. 1992; 75:17-9.
    View PubMed
  49. Ingle JN, Twito DI, Schaid DJ, Cullinan SA, Krook JE, Mailliard JA, Tschetter LK, Long HJ, Gerstner JG, Windschitl HE, Levitt R, Pfeifle DM. Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer: an updated analysis. Pages 169-71 in:. The Yearbook of Oncology RC Young RC, Editor St , 1992 1992; Louis:Mosby.
  50. Long HJ, Wieand HS, Foley JF, Niedringhaus RD, Laurie JA, Morton RF, Goldberg RM, Mailliard JA, Malkasian GD, Edmonson JH. Phase II evaluation of menogaril in patients with advanced cervical carcinoma: a collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic. Invest New Drugs. 1991 Nov; 9:349-51.
  51. Long HJ 3rd, Laurie JA, Wieand HS, Edmonson JH, Levitt R, Krook JE, Abu-Ghazaleh S. A phase II evaluation of menogaril in cisplatin-refractory advanced ovarian carcinoma. A collaborative trial of the North Central Cancer Treatment Group and the Mayo Clinic. Cancer. 1991 Aug 15; 68(4):730-2.
  52. Long HJ, Hauge MD, Therneau TM, Buckner JC, Frytak S, Hahn RG. Phase II evaluation of menogaril in patients with advanced hypernephroma. Invest New Drugs. 1991 Aug; 9(3):261-2.
    View PubMed
  53. Ahmann DL, Schaid DJ, Ingle JN, Bisel HF, Schutt AJ, Buckner JC, Long HJ, Rubin J. A randomized trial of cyclophosphamide, doxorubicin, and prednisone versus cyclophosphamide, 5-fluorouracil, and prednisone in patients with metastatic breast cancer. Am J Clin Oncol. 1991 Jun; 14(3):179-83.
    View PubMed
  54. Ingle JN, Twito DI, Schaid DJ, Cullinan SA, Krook JE, Mailliard JA, Tschetter LK, Long HJ, Gerstner JG, Windschitl HE. Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis. Cancer. 1991 Feb 15; 67(4):886-91.
    View PubMed
  55. Elg S, Halberg E, Ramakrishnan S, Cornelissen G, Haus E, Nicolau G, Carson L, Twiggs L, Long HJ III, Halberg F. Marker rhythmometry with M-CSF. Chronobiologia. 1991; 18:141-52.
    View PubMed
  56. Cornelissen G, Halberg E, Long HJ III, Prem K, Bakken E, Touitou Y, Elg S, Haus E, Halberg F. Toward a chronotherapy of ovarian cancer with taxol. Part I: basic background. Chronobiologia. 1991; 18:153-66.
    View PubMed
  57. Ingle JN, Mailliard JA, Schaid DJ, Krook JE, Gesme DH, Windschitl HE, Pfeifle DM, Etzell PS, Gerstner JG, Long HJ, Foley JF, Loprinzi CL, Dalton RJ. A double-blind trial of tamoxifen plus prednisone versus tamoxifen plus placebo in postmenopausal women with metastatic breast cancer. Cancer. 1991; 68:34-39.
    View PubMed
  58. Creagan ET, Long HJ, Ahmann DL, Schaid DJ. Phase II assessment of recombinant leukocyte A interferon with difluoromethylornithine in disseminated malignant melanoma. Am J Clin Oncol. 1990 Jun; 13(3):218-20.
    View PubMed
  59. Ingle JN, Krook JE, Schaid DJ, Everson LK, Mailliard JA, Long HJ, McCormack GW. Evaluation of trilostane plus hydrocortisone in women with metastatic breast cancer and prior hormonal therapy exposure. Am J Clin Oncol. 1990 Apr; 13(2):93-7.
    View PubMed
  60. Ingle JN, Mailliard JA, Schaid DJ, Krook JE, Gerstner JB, Pfeifle DM, Marschke RF, Long HJ, McCormack GW, Foley JF. Randomized trial of doxorubicin alone or combined with vincristine and mitomycin C in women with metastatic breast cancer. Am J Clin Oncol. 1989 Dec; 12(6):474-80.
    View PubMed
  61. De Fusco PA, Gaffey TA, Malkasian GD, Long HJ, Cha SS. Endometrial stromal sarcoma: review of Mayo Clinic experience, 1945-1980. Gynecol Oncol. 1989 Oct; 35(1):8-14.
    View PubMed
  62. Creagan ET, Frytak S, Long HJ, Kvols LK. Phase I study of recombinant leukocyte A interferon (IFN-alpha 2A, Roferon-A) with doxorubicin in advanced malignant disease. Cancer. 1989 Sep 1; 64(5):1034-7.
    View PubMed
  63. Edmonson JH, Buckner JC, Long HJ, Loprinzi CL, Schaid DJ. Phase II study of ifosfamide-etoposide-mesna in adults with advanced nonosseous sarcomas. J Natl Cancer Inst. 1989 Jun 7; 81(11):863-6.
    View PubMed


Appointments | Contact Us | Give to Mayo Clinic | Search

LEGAL RESTRICTIONS AND TERMS OF USE APPLICABLE TO THIS SITE

Use of this site signifies your agreement to the terms of use.
© 2013 Mayo Foundation for Medical Education and Research. All rights reserved.